Details for Patent: 11,759,446
✉ Email this page to a colleague
Which drugs does patent 11,759,446 protect, and when does it expire?
Patent 11,759,446 protects HETLIOZ and HETLIOZ LQ and is included in two NDAs.
This patent has thirteen patent family members in twelve countries.
Drugs Protected by US Patent 11,759,446
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vanda Pharms Inc | HETLIOZ | tasimelteon | CAPSULE;ORAL | 205677-001 | Jan 31, 2014 | AB | RX | Yes | Yes | 11,759,446 | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Subscribe | |||
| Vanda Pharms Inc | HETLIOZ LQ | tasimelteon | SUSPENSION;ORAL | 214517-001 | Dec 1, 2020 | RX | Yes | Yes | 11,759,446 | ⤷ Subscribe | TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,759,446
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020400065 | ⤷ Subscribe | |||
| Canada | 3161975 | ⤷ Subscribe | |||
| Chile | 2022001546 | ⤷ Subscribe | |||
| China | 114727978 | ⤷ Subscribe | |||
| Colombia | 2022009691 | ⤷ Subscribe | |||
| European Patent Office | 4072542 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
